Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
Interest Income Expense
Apontis Pharma AG
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Apontis Pharma AG
XETRA:APPH
|
Interest Income Expense
-€20k
|
CAGR 3-Years
71%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Interest Income Expense
-$1.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Interest Income Expense
-€2.2B
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-12%
|
|
|
Merck KGaA
XETRA:MRK
|
Interest Income Expense
-€74m
|
CAGR 3-Years
34%
|
CAGR 5-Years
28%
|
CAGR 10-Years
10%
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Interest Income Expense
-€64.3m
|
CAGR 3-Years
-99%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
N/A
|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Interest Income Expense
-€2.7m
|
CAGR 3-Years
-203%
|
CAGR 5-Years
-221%
|
CAGR 10-Years
N/A
|
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
See Also
What is Apontis Pharma AG's Interest Income Expense?
Interest Income Expense
-20k
EUR
Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Interest Income Expense amounts to -20k EUR.
What is Apontis Pharma AG's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
71%
The average annual Interest Income Expense growth rates for Apontis Pharma AG have been 71% over the past three years .
You don't have any saved screeners yet